cabergoline + levodopa
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Restless Legs Syndrome
Conditions
Restless Legs Syndrome
Trial Timeline
Jan 1, 2003 → Dec 1, 2004
NCT ID
NCT00625547About cabergoline + levodopa
cabergoline + levodopa is a phase 3 stage product being developed by Pfizer for Restless Legs Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT00625547. Target conditions include Restless Legs Syndrome.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00153972 | Approved | Completed |
| NCT00625547 | Phase 3 | Completed |
Competing Products
20 competing products in Restless Legs Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Gabapentin enacarbil | Astellas Pharma | Approved | 85 |
| ASP8825 | Astellas Pharma | Phase 3 | 77 |
| Regnite | Astellas Pharma | Pre-clinical | 23 |
| ASP8825 + Placebo | Astellas Pharma | Phase 2 | 52 |
| Placebo + Gabapentin enacarbil | Astellas Pharma | Approved | 85 |
| Apomorphine Sublingual Film + Placebo | Sumitomo Pharma | Approved | 85 |
| Suvorexant | Merck | Approved | 85 |
| Cabergoline | Pfizer | Phase 3 | 76 |
| Placebo + pregabalin + pregabalin | Pfizer | Phase 3 | 76 |
| placebo + Pregabalin + Pregabalin + Pregabalin + Pregabalin + Pregabalin | Pfizer | Phase 2 | 51 |
| pregabalin + placebo + pramipexole | Pfizer | Phase 3 | 76 |
| placebo and pregabalin + pramipexol + pramipexol + Pregabalin + pramipexol + pramipexol | Pfizer | Phase 3 | 76 |
| Rotigotine | UCB | Phase 3 | 74 |
| Neupro® | UCB | Pre-clinical | 20 |
| Rotigotine Nasal Spray | UCB | Phase 2 | 49 |
| Rotigotine | UCB | Phase 3 | 74 |
| Levetiracetam (Keppra) | UCB | Phase 2 | 49 |
| Rotigotine + Placebo | UCB | Approved | 82 |
| Rotigotine | UCB | Phase 2 | 49 |
| Rotigotine | UCB | Phase 3 | 74 |